Figure 4. Patient clinical course. (A-D)... | American Society of Hematology

Figure 4.

$Patient clinical course. (A-D) Marrow blasts as percentage of white blood cells (WBC) (red lines, left y-axis) and absolute count of HA-1 TCR-T (blue lines, right y-axis) are shown for the 4 participants with treatment response. Vertical dashed lines denote HCT or infusion time points. The horizontal dashed line indicates limit of detection for HA-1 TCR-T (0.02 cells per μl). (A) Patient 3 received 2 escalating dose infusions (DL1, DL2), the first at the time of rapidly proliferating T-ALL, resulting in a 6-month remission. Concurrent with falling blood concentrations of TCR-T, he experienced relapse. A third DL infusion given in the context of overwhelming, chemorefractory marrow and extramedullary T-ALL had no effect. (B) Patient 9 had 38% AML in the marrow before receiving a single DL3 infusion, resulting in a complete remission of up to 12 weeks (CRi documented at 3 and 5 weeks, relapse at 12 weeks). (C) Patient 1 entered the trial in an MRD-negative state after serial salvage therapies. He received 1 TCR-T infusion (DL1, CD8 only) with no subsequent pharmacologic maintenance, sustained MRD-negative status through 3 months after infusion, with eventual MRD detection at month 6. He received a second (DL1) and third (DL2, not shown) infusion in the context of MRD, but did not regain MRD-negative CR. (D) Patient 8 had high-risk, TP53+ MDS. She received 1 infusion (DL3) after salvage with hypomethylating therapy and venetoclax and sustained MRD-negative remission following HA-1 TCR-T.$

Patient clinical course. (A-D) Marrow blasts as percentage of white blood cells (WBC) (red lines, left y-axis) and absolute count of HA-1 TCR-T (blue lines, right y-axis) are shown for the 4 participants with treatment response. Vertical dashed lines denote HCT or infusion time points. The horizontal dashed line indicates limit of detection for HA-1 TCR-T (0.02 cells per μl). (A) Patient 3 received 2 escalating dose infusions (DL1, DL2), the first at the time of rapidly proliferating T-ALL, resulting in a 6-month remission. Concurrent with falling blood concentrations of TCR-T, he experienced relapse. A third DL infusion given in the context of overwhelming, chemorefractory marrow and extramedullary T-ALL had no effect. (B) Patient 9 had 38% AML in the marrow before receiving a single DL3 infusion, resulting in a complete remission of up to 12 weeks (CRi documented at 3 and 5 weeks, relapse at 12 weeks). (C) Patient 1 entered the trial in an MRD-negative state after serial salvage therapies. He received 1 TCR-T infusion (DL1, CD8 only) with no subsequent pharmacologic maintenance, sustained MRD-negative status through 3 months after infusion, with eventual MRD detection at month 6. He received a second (DL1) and third (DL2, not shown) infusion in the context of MRD, but did not regain MRD-negative CR. (D) Patient 8 had high-risk, TP53+ MDS. She received 1 infusion (DL3) after salvage with hypomethylating therapy and venetoclax and sustained MRD-negative remission following HA-1 TCR-T.

This Feature Is Available To Subscribers Only